ArticleBlood advances2024

The use of metformin and risk of myeloproliferative neoplasms among patients with no registered markers of diabetes.

Daniel Tuyet Kristensen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.